- Not Fee assured
- Verified this account
I hold the post of Professor in Interventional Oncology at University College London and am Associate Professor at Middlesex University, London. At UCLH I am Pathway Director for Urological Cancer for UCL Partners. I am also Honorary Clinical Director of the Clinical Effectiveness Unit at the Royal College of Surgeons of England.
My clinical and research interests are focused mainly on diseases of the prostate gland, both benign and malignant. In prostate cancer much of my activity is at present focused on evaluating minimally invasive therapies for localised prostate cancer. This work encompasses the fields of precise characterisation of disease as well as targeting therapies. A current interest includes the non invasive evaluation of men at risk of having prostate cancer.
I am also interested in the methodological aspects of clinical research, particularly on the use of alternatives to the randomised control trial in surgery. I am involved in guideline production and appraisal and am interested in the formulation of evidence based management policies.
I am an active researcher, lecture widely and have published over 100 peer reviewed publications as well as numerous books and chapters. I am a founding Partner of London Urology Associates, and is a Trustee of Prostate Action.
Areas of interest
Prostate disease including prostate cancer; Urological oncology
- Nina Reeve
- London Urology Associates 18 Devonshire Street London W1G 7AF
- 020 7224 5089
Anaesthetists worked with (Bupa members, please ask your consultant whether your anaesthetist is fee-assured)
High intesntivy focused ultrasound
Vascular targetted therapy
Reference number 3098619
Information for healthcare professionals (Bupa patients only, last 12 months)
Transperineal template-guided biopsies of the prostate under image guidance - (>50)
Diagnostic endoscopic examination of bladder (flexible cystoscopy) including any biopsy - (5-50)
IV sedation administered by operator - (5-50)
Introduction of substance into skin (including hormone pellet) - (5-50)
Percutaneous thermal coagulation of mass - (5-50)
- Show All (8)...